Table of Contents

Research Articles

• Research Articles | AuthorChoice

  In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

  Changyu Wang, Kent B. Thudium, Minhua Han, Xi-Tao Wang, Haichun Huang, Diane Feingersh, Candy Garcia, Yi Wu, Michelle Kuhne, Mohan Srinivasan, Sujata Singh, Susan Wong, Neysa Garner, Heidi Leblanc, R. Todd Bunch, Diann Blanset, Mark J. Selby and Alan J. Korman

  Cancer Immunol Res September 1 2014 2 (9) 846-856; DOI:10.1158/2326-6066.CIR-14-0040

  
  

  Wang and colleagues describe the development and comprehensive preclinical characterization of nivolumab, a fully human IgG4 (S228P) anti-PD-1 receptor blocking mAb, the antitumor activity and safety profile of which has been demonstrated in human clinical trials in various solid tumors.
• Research Articles | AuthorChoice

  Mechanisms That Can Promote Peripheral B-cell Lymphoma in ATM-Deficient Mice

  Suprawee Tepsuporn, Jiazhi Hu, Monica Gostissa and Frederick W. Alt

  Cancer Immunol Res September 1 2014 2 (9) 857-866; DOI:10.1158/2326-6066.CIR-14-0090

  
  

  Tepsuporn, Hu, and colleagues generated the first mouse models for B-cell lymphoma in the context of ATM deficiency, and they provide a detailed characterization of the mature B-cell lymphomas that arise, revealing an unanticipated mechanism for the developmental propagation of V(D)J recombination-initiated DNA double-strand breaks.
• Research Articles

  Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy

  Brett Schrand, Alexey Berezhnoy, Randall Brenneman, Anthony Williams, Agata Levay, Ling-Yuan Kong, Ganesh Rao, Shouhao Zhou, Amy B. Heimberger and Eli Gilboa

  Cancer Immunol Res September 1 2014 2 (9) 867-877; DOI:10.1158/2326-6066.CIR-14-0007

  
  

  Schrand and colleagues report the efficacy in five murine tumor models of an immunotherapeutic approach whereby systemic administration of tumor stroma-targeted 4-1BB aptamer conjugates, which target disseminated tumor lesions, elicits potent antitumor immunity with minimal dose-limiting toxicity.
• Research Articles

  CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

  Juan Du, Sandra Lopez-Verges, Brandelyn N. Pitcher, Jeffrey Johnson, Sin-Ho Jung, Lili Zhou, Katharine Hsu, Myron S. Czuczman, Bruce Cheson, Lawrence Kaplan, Lewis L. Lanier and Jeffrey M. Venstrom

  Cancer Immunol Res September 1 2014 2 (9) 878-889; DOI:10.1158/2326-6066.CIR-13-0158

  
  

  Du and colleagues report that a “missing ligand” genotype predictive of unlicensed NK cells was associated with higher progression-free survival in 101 follicular lymphoma patients treated with rituximab-containing mAb combinations, and that rituximab triggered responses in vitro from healthy-donor unlicensed NK cells.
• Research Articles

  IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization

  Hanako Ohmatsu, Daniel Humme, Nicholas Gulati, Juana Gonzalez, Markus Möbs, Mayte Suárez-Fariñas, Irma Cardinale, Hiroshi Mitsui, Emma Guttman-Yassky, Wolfram Sterry and James G. Krueger

  Cancer Immunol Res September 1 2014 2 (9) 890-900; DOI:10.1158/2326-6066.CIR-13-0199-T

  
  

  Ohmatsu and colleagues report the consistently high and increasing expression of IL32 in cutaneous T-cell lymphoma mycosis fungoides (MF) compared with benign inflammatory skin diseases, and these findings correlate with increases in IFNγ mRNA, suggesting that IL32 may be an autocrine cytokine in MF progression.
• Research Articles

  STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer

  Dinesh Chandra, Wilber Quispe-Tintaya, Arthee Jahangir, Denise Asafu-Adjei, Ilyssa Ramos, Herman O. Sintim, Jie Zhou, Yoshihiro Hayakawa, David K.R. Karaolis and Claudia Gravekamp

  Cancer Immunol Res September 1 2014 2 (9) 901-910; DOI:10.1158/2326-6066.CIR-13-0123

  
  

  Chandra, Quispe-Tintaya, and colleagues show that stimulator of IFN genes (STING) ligand c-di-GMP activated caspase-3, stimulated T cells, and nearly completely eliminated all metastases in mouse breast cancer model 4T1, when combined with Listeria monocytogenes–based Mage-b vaccine in a therapeutic setting.
• Research Articles | AuthorChoice

  Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4⁺FoxP3⁻ and CD8⁺ T Cells

  Zhisong Chen, Laurent Ozbun, Namju Chong, Anu Wallecha, Jay A. Berzofsky and Samir N. Khleif

  Cancer Immunol Res September 1 2014 2 (9) 911-922; DOI:10.1158/2326-6066.CIR-13-0197

  
  

  Chen and colleagues developed an improved, attenuated L. monocytogenes–based vaccine that induced the regression of established mouse TC-1 tumors; they show that listeriolysin O serves as a vaccine adjuvant that decreases Treg frequency by inducing the expansion of non-Treg T cells.